Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: THY025
MIFTS: 60

Thymus Cancer

Categories: Cancer diseases, Rare diseases, Immune diseases, Endocrine diseases, Genetic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Thymus Cancer

About this section

MalaCards integrated aliases for Thymus Cancer:

Name: Thymus Cancer 12 43 15
Thymic Carcinoma 12 76 59 55 15 73
Malignant Thymoma 12 59
Thymus Neoplasms 44 73
Malignant Neoplasm of Thymus 73
Neoplasm of Thymus 12
Thymoma, Malignant 12
Thymoma, Familial 73
Thymic Neoplasm 12
Thymoma, Type C 73
Thymus Neoplasm 76
Thymic Tumor 12

Characteristics:

Orphanet epidemiological data:

59
thymic carcinoma
Inheritance: Not applicable; Age of onset: Adult; Age of death: any age;

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases Genetic diseases
Anatomical: Immune diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33 34


Sources

Summaries for Thymus Cancer

About this section
MedlinePlus : 43 The thymus is a small organ in your upper chest, under your breastbone. Before birth and during childhood, the thymus helps the body make a type of white blood cell. These cells help protect you from infections. Cancer of the thymus is rare. You are more likely to get it if you have other diseases such as myasthenia gravis, lupus or rheumatoid arthritis. Sometimes there are no symptoms. Other times, thymus cancer can cause A cough that doesn't go away Chest pain Trouble breathing Doctors use a physical exam, imaging tests, and a biopsy to diagnose thymus cancer. The most common treatment is surgery to remove the tumor. Other options include radiation therapy, chemotherapy, and hormone therapy. NIH: National Cancer Institute

MalaCards based summary : Thymus Cancer, also known as thymic carcinoma, is related to thymoma and large cell carcinoma. An important gene associated with Thymus Cancer is CD5 (CD5 Molecule), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Downstream signaling events of B Cell Receptor (BCR). The drugs Fentanyl and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include thymus, testes and lung, and related phenotypes are hyperhidrosis and weight loss

Disease Ontology : 12 A thymus cancer that derives from epithelial cells. The tumor cells in a thymic carcinoma look very different from the normal cells of the thymus, grow more quickly, and have usually spread to other parts of the body when the cancer is found.

Wikipedia : 76 Thymic carcinoma is a rare type of thymus gland cancer. It usually spreads, has a high risk of... more...

Sources

Related Diseases for Thymus Cancer

About this section

Diseases related to Thymus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 215)
# Related Disease Score Top Affiliating Genes
1 thymoma 30.2 CD5 DNTT DPYSL5 KIT NKX2-1
2 large cell carcinoma 29.4 EGFR KRT5 KRT7 NKX2-1 SYP
3 lymphoepithelioma-like thymic carcinoma 12.1
4 thymus adenocarcinoma 11.4
5 thymoma, familial 11.3
6 epithelial malignant thymoma 11.3
7 thymus squamous cell carcinoma 11.2
8 immunodeficiency with thymoma 11.1
9 thymic epithelial tumor 11.0 CD5 KIT
10 thymus adenosquamous carcinoma 11.0
11 ovary neuroendocrine neoplasm 11.0 KRT7 SYP
12 invasive malignant thymoma 10.9
13 noninvasive malignant thymoma 10.9
14 reticular perineurioma 10.9 KIT MUC1
15 mixed type thymoma 10.9 CD5 KIT SYP
16 jejunal cancer 10.9 KIT KRT7
17 ovarian large-cell neuroendocrine carcinoma 10.9 KRT7 SYP
18 mucinous adenofibroma 10.9 KRT7 SYP
19 ovarian germ cell teratoma 10.8 KRT7 NKX2-1
20 breast lymphoma 10.8 CD5 SMUG1
21 small cell carcinoma of the bladder 10.8 KRT7 NKX2-1 SYP
22 spindle cell thymoma 10.8 CD5 MUC1
23 sinonasal undifferentiated carcinoma 10.8 MUC1 SYP
24 immune system organ benign neoplasm 10.8 CD5 KRT7 SYP
25 pulmonary sclerosing hemangioma 10.8 KRT7 NKX2-1 SYP
26 thymus lipoma 10.8 CD5 KRT7 SYP
27 endometrial small cell carcinoma 10.8 KIT SMUG1 SYP
28 gallbladder small cell carcinoma 10.8 SMUG1 SYP
29 gallbladder squamous cell carcinoma 10.8 SMUG1 TP53
30 bartholin's duct cyst 10.8 SMUG1 TP53
31 cutaneous ganglioneuroma 10.8 KIT SYP
32 inverted transitional papilloma 10.8 KRT5 KRT7
33 perivascular epithelioid cell tumor 10.8 KIT MUC1 SYP
34 solid adenocarcinoma with mucin production 10.8 KRT7 MUC1 NKX2-1
35 malignant mixed mullerian tumor 10.8 KIT KRT7 MUC1
36 extraskeletal ewing sarcoma 10.8 MUC1 NKX2-1 SYP
37 balloon cell malignant melanoma 10.8 KRT5 KRT7
38 dermoid cyst 10.7 KIT KRT7 MUC1
39 lung acinar adenocarcinoma 10.7 KRT7 NKX2-1
40 uterine body mixed cancer 10.7 KIT PIK3R2 TP53
41 ampulla of vater neoplasm 10.7 KRT7 MUC1 SYP
42 cavernous hemangioma 10.7 KIT MUC1 SYP
43 papillary serous adenocarcinoma 10.7 KRT7 NKX2-1 TP53
44 cellular ependymoma 10.7 SMUG1 SYP TP53
45 neurofibroma 10.7 KIT MUC1 SYP
46 glycogen-rich clear cell breast carcinoma 10.7 KRT7 SYP TP53
47 gastric tubular adenocarcinoma 10.7 KRT7 MUC1 SYP
48 endosalpingiosis 10.7 KRT7 MUC1
49 cystadenoma 10.7 KRT7 MUC1 SYP
50 papillary tumor of the pineal region 10.7 MUC1 SYP

Graphical network of the top 20 diseases related to Thymus Cancer:



Diseases related to Thymus Cancer
Sources

Symptoms & Phenotypes for Thymus Cancer

About this section

Human phenotypes related to Thymus Cancer:

59 32 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000975
2 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
3 dyspnea 59 32 frequent (33%) Frequent (79-30%) HP:0002094
4 fatigable weakness 59 32 occasional (7.5%) Occasional (29-5%) HP:0003473
5 diaphragmatic paralysis 59 32 frequent (33%) Frequent (79-30%) HP:0006597
6 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378
7 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
8 neoplasm of the thymus 59 32 hallmark (90%) Very frequent (99-80%) HP:0100521
9 palpebral edema 59 32 frequent (33%) Frequent (79-30%) HP:0100540
10 mediastinal lymphadenopathy 59 32 frequent (33%) Very frequent (99-80%) HP:0100721
11 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749
12 edema 59 Frequent (79-30%)
13 abnormality of the vena cava 59 Frequent (79-30%)
14 ptosis 32 occasional (7.5%) HP:0000508
15 cardiac arrest 32 occasional (7.5%) HP:0001695
16 pericarditis 32 occasional (7.5%) HP:0001701
17 abnormal bleeding 32 occasional (7.5%) HP:0001892
18 dysphagia 32 occasional (7.5%) HP:0002015
19 headache 32 occasional (7.5%) HP:0002315
20 language impairment 32 occasional (7.5%) HP:0002463
21 increased intracranial pressure 32 occasional (7.5%) HP:0002516
22 immunodeficiency 32 frequent (33%) HP:0002721
23 autoimmunity 32 occasional (7.5%) HP:0002960
24 dysgammaglobulinemia 32 frequent (33%) HP:0002961
25 neuroendocrine neoplasm 32 occasional (7.5%) HP:0100634
26 abnormal vena cava morphology 32 frequent (33%) HP:0005345

GenomeRNAi Phenotypes related to Thymus Cancer according to GeneCards Suite gene sharing:

26 (show all 26)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.83 POMC
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.83 PIK3R2 POMC DNTT KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.83 PIK3R2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.83 PIK3R2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.83 DNTT
6 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.83 POMC
7 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.83 DNTT
8 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.83 DNTT
9 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.83 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.83 DNTT KIT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.83 DNTT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.83 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-182 9.83 DNTT
14 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.83 DNTT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.83 PIK3R2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.83 POMC
17 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.83 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.83 POMC
19 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.83 KIT
20 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.83 PIK3R2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.83 DNTT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.83 PIK3R2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.83 KIT PIK3R2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.83 POMC
25 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.83 POMC KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.83 KIT

MGI Mouse Phenotypes related to Thymus Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.06 KIT KRT5 AMPH NKX2-1 CALB2 POMC
2 nervous system MP:0003631 9.97 NKX2-1 AMPH CALB2 CD5 POMC CNTNAP2
3 neoplasm MP:0002006 9.8 KIT NKX2-1 PIK3R2 POMC SMUG1 EGFR
4 no phenotypic analysis MP:0003012 9.61 KRT5 NKX2-1 CD5 POMC PSMB11 EGFR
5 normal MP:0002873 9.28 KIT NKX2-1 CALB2 CD5 DNTT SYP
Sources

Drugs & Therapeutics for Thymus Cancer

About this section

Drugs for Thymus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
4 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
5 Liver Extracts Phase 3,Phase 1
6 Adjuvants, Anesthesia Phase 3
7 Analgesics Phase 3,Phase 1,Phase 2
8 Analgesics, Opioid Phase 3
9 Anesthetics Phase 3
10 Anesthetics, General Phase 3
11 Anesthetics, Intravenous Phase 3
12 Central Nervous System Depressants Phase 3
13 Narcotics Phase 3
14 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
16 Etoposide phosphate Phase 3,Phase 2,Phase 1
17 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
18 Cola Nutraceutical Phase 3,Phase 1,Not Applicable
19
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
20
Bevacizumab Approved, Investigational Phase 2 216974-75-3
21
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
22
Belinostat Approved, Investigational Phase 2,Phase 1 866323-14-0
23
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
24
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
25
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
26
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
27
Busulfan Approved, Investigational Phase 2 55-98-1 2478
28
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
29
Melphalan Approved Phase 2 148-82-3 4053 460612
30
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
31
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
32
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
33
Rabeprazole Approved, Investigational Phase 1, Phase 2 117976-89-3 5029
34
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
35
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
36
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
37
nivolumab Approved Phase 2 946414-94-4
38
Coal tar Approved Phase 1, Phase 2 8007-45-2
39 Amrubicin Approved, Investigational Phase 2 110267-81-7
40
Everolimus Approved Phase 2 159351-69-6 6442177
41
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
42
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
43
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
44
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5005498 5330286
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
46
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 143 6006
47
Lapatinib Approved March 2007, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
48
Maleic acid Experimental Phase 2 110-16-7 444266
49
Doxil Approved June 1999 Phase 2,Phase 1 31703
50
Saracatinib Investigational Phase 2 379231-04-6

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
3 Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
4 A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
5 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
6 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
7 Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage Completed NCT00589290 Phase 2 Belinostat (PDX101)
8 Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity Completed NCT01163552 Phase 2
9 Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
10 Preoperative Treatment of Patients With High Risk Thymoma Completed NCT00387868 Phase 2 cisplatin and etoposide
11 Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
12 Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases Completed NCT00003662 Phase 2 busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
13 Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Completed NCT00024076 Phase 2
14 Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors Completed NCT01283945 Phase 1, Phase 2 Lucitanib
15 Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions Completed NCT00003336 Phase 2 busulfan;cyclophosphamide;melphalan;methylprednisolone
16 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
17 Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma Recruiting NCT02364076 Phase 2 Pembrolizumab;Epacadostat
18 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Recruiting NCT01306045 Phase 2 AZD6244;MK-2206;Lapatinib;Erlotinib;Sunitinib
19 Study of Chemoradiotherapy for Inoperable Locally Advanced (Stage â…¢/â…£a) Thymoma or Thymic Carcinoma Recruiting NCT02636556 Phase 2
20 Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) Recruiting NCT03134118 Phase 2 Nivolumab
21 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
22 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Recruiting NCT03449173 Phase 2 Sunitinib
23 Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma Recruiting NCT03466827 Phase 2 Selinexor
24 Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy Recruiting NCT03193437 Phase 2 Open Label Selinexor
25 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Recruiting NCT02810418 Phase 1, Phase 2 LMB-100;Nab-Paclitaxel
26 Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Active, not recruiting NCT01621568 Phase 2 Sunitinib
27 A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Active, not recruiting NCT01364727 Phase 2 Amrubicin
28 Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Active, not recruiting NCT02049047 Phase 2 Everolimus
29 A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Active, not recruiting NCT02623127 Phase 2 Sunitinib
30 Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Active, not recruiting NCT01011439 Phase 2 Milciclib Maleate
31 Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Active, not recruiting NCT01025089 Phase 2 Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
32 Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy Active, not recruiting NCT01301391 Phase 2 Milciclib Maleate
33 A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor Not yet recruiting NCT03219554 Phase 2 Palbociclib
34 Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer Suspended NCT03463460 Phase 2 Sunitinib Malate
35 Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Suspended NCT02054104 Phase 1, Phase 2 Cyclophosphamide;Celecoxib
36 Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer Terminated NCT00718809 Phase 2 saracatinib
37 A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Terminated NCT01100944 Phase 1, Phase 2 PXD101with cisplatin+doxorubicin+cyclophosphamide
38 Paclitaxel and Cisplatin for Thymic Neoplasm Terminated NCT00818090 Phase 2 paclitaxel and cisplatin
39 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
40 Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas Completed NCT01143545 Phase 1 Celecoxib;cyclophosphamide
41 Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma Completed NCT00314873 Phase 1 Gleevec (imatinib)
42 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
43 Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03295227 Phase 1 Pembrolizumab
44 Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Recruiting NCT03023319 Phase 1 Bosutinib;Pemetrexed
45 Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors Recruiting NCT03102320 Phase 1 Cisplatin;Gemcitabine;Anetumab ravtansine (BAY94-9343)
46 Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies Active, not recruiting NCT01165658 Phase 1
47 Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies Active, not recruiting NCT00921739 Phase 1
48 Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer Unknown status NCT00372840 Not Applicable
49 Genetic Evaluation of Families With Endocrine Cancers Completed NCT01794676
50 Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors Completed NCT02233842

Search NIH Clinical Center for Thymus Cancer

Cochrane evidence based reviews: thymus neoplasms

Sources

Genetic Tests for Thymus Cancer

About this section
Sources

Anatomical Context for Thymus Cancer

About this section

MalaCards organs/tissues related to Thymus Cancer:

41
Thymus, Testes, Lung, Thyroid, Prostate, Liver, Brain
Sources

Publications for Thymus Cancer

About this section

Articles related to Thymus Cancer:

(show top 50) (show all 391)
# Title Authors Year
1
Concurrent thymic carcinoma and middle lobe syndrome. ( 29600097 )
2018
2
Thymoma and thymic carcinoma associated with multilocular thymic cyst: a clinicopathologic analysis of 18 cases. ( 29945642 )
2018
3
Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. ( 29702286 )
2018
4
Spontaneous remission in large-vessel vasculitis: Takayasu arteritis and paraneoplastic disorder associated with thymic carcinoma. ( 29974801 )
2018
5
Diffuse Alveolar Hemorrhage Induced by Irinotecan for a Patient with Metastatic Thymic Carcinoma: A Case Report and Literature Review. ( 28674360 )
2017
6
Multicentric reticulohistiocytosis associated with thymic carcinoma. ( 28633354 )
2017
7
Correction: Long term oncological outcome of thymoma and thymic carcinoma - an analysis of 235 cases from a single institution. ( 28931090 )
2017
8
Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas. ( 28179162 )
2017
9
Rare Case of Spinal Cord Compression as Initial Presentation of Thymic Carcinoma. ( 29147447 )
2017
10
High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma. ( 28550415 )
2017
11
A rare highly aggressive tumour: lymphoepithelioma-like thymic carcinoma. ( 28942409 )
2017
12
LAT1 acts as a crucial transporter of amino acids in human thymic carcinoma cells. ( 27567475 )
2016
13
Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma. ( 27166394 )
2016
14
Tumor-related gene expression levels in thymic carcinoma and Type B3 thymoma. ( 27387303 )
2016
15
Thymic carcinoma with myasthenia gravis: Two case reports. ( 27591911 )
2016
16
Thymic carcinoma presenting with an unusual and delayed metastasis to the neural foramen, mimicking thoracic spinal radiculopathy. ( 28087968 )
2016
17
Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report. ( 27123268 )
2016
18
c-kit mutation-positive advanced thymic carcinoma successfully treated as a mediastinal gastrointestinal stromal tumor: A case report. ( 27073655 )
2016
19
The enlightenments from ITMIG Consensus on WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. ( 27114842 )
2016
20
Erratum: Omasa M, Date H, Sozu T, Sato T, Nagai K, Yokoi K, Okamoto T, Ikeda N, Tanaka F, and Maniwa Y, and the Japanese Association for Research on the Thymus. Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: The Japanese Association for Research on the Thymus Database Study. Cancer. doi: 10.1002/cncr.29166. ( 26057775 )
2015
21
Two Cases of Thymic Carcinoma Initially Presenting as Bone Metastasis: A Clinical Report and the Usefulness of CD5 Immunohistochemistry for Assessing Bone Lesions. ( 26179536 )
2015
22
Response to cytotoxic chemotherapy in patients previously treated with palliative-intent chemotherapy for advanced thymic carcinoma. ( 25468802 )
2015
23
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. ( 25592632 )
2015
24
Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. ( 25799277 )
2015
25
Adenocarcinoma of the thymus, enteric type: report of 2 cases, and proposal for a novel subtype of thymic carcinoma. ( 25517960 )
2015
26
Concurrent thymoma, thymic carcinoma, and T lymphoblastic leukemia/lymphoma in an anterior mediastinal mass. ( 26150396 )
2015
27
Clear cell thymic carcinoma: a case report. ( 25702670 )
2015
28
The role of CD5 expression in thymic carcinoma: possible mechanism for interaction with CD5(+) lymphoid stroma (microenvironment). ( 26018940 )
2015
29
Sunitinib effective for rare thymus cancer. ( 25680712 )
2015
30
Pathologic Finding of Thymic Carcinoma Accompanied by Myasthenia Gravis. ( 26320843 )
2015
31
Staging of thymic epithelial neoplasms: thymoma and thymic carcinoma. ( 25441660 )
2015
32
Treatment and prognosis of Masaoka stage 3 thymic carcinoma: a retrospective study of 32 cases. ( 25897244 )
2015
33
Repeated Localized Treatment for Endobronchial Metastasis of Thymic Carcinoma. ( 26204486 )
2015
34
Rare case of subcarinal thymic carcinoma in the middle mediastinum. ( 25813154 )
2015
35
Radical surgical resection of advanced thymoma and thymic carcinoma infiltrating the heart or great vessels with cardiopulmonary bypass support. ( 26515387 )
2015
36
Thymic carcinoma outcomes and prognosis: results of an international analysis. ( 25524678 )
2015
37
Long-Term Survival After Surgical Treatment of Thymic Carcinoma: A Retrospective Analysis from the Chinese Alliance for Research of Thymoma Database. ( 26474558 )
2015
38
Thymic carcinoma patients with myasthenia gravis exhibit better prognoses. ( 26138264 )
2015
39
Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: The Japanese Association for Research on the Thymus Database Study. ( 25565590 )
2015
40
Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors. ( 26317915 )
2015
41
Response to nab-paclitaxel and nedaplatin in a heavily-metastatic thymic carcinoma: A case report. ( 25789028 )
2015
42
Thymoma and thymic carcinoma in children and adolescents: A report from the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT). ( 26259494 )
2015
43
Treatment and survival analyses of completely resected thymic carcinoma patients. ( 26392777 )
2015
44
Docetaxel for platinum-refractory advanced thymic carcinoma. ( 25840444 )
2015
45
Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study. ( 26116920 )
2015
46
Locally advanced thymic carcinoma with direct pericardial extension and atrial clot diagnosed with endoscopic ultrasound: a case report. ( 25504479 )
2015
47
Sunitinib in thymic carcinoma: enigmas still unresolved. ( 25592633 )
2015
48
Long-term outcomes of surgery for thymic carcinoma: experience of 25 cases at a single institution. ( 25629460 )
2015
49
Rarest of a rare disease: challenges in advancing our knowledge of thymic carcinoma. ( 25524680 )
2015
50
Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. ( 24855380 )
2014
Sources

Variations for Thymus Cancer

About this section

Cosmic variations for Thymus Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM44380 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 14
2 COSM14140 SMAD4 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1081C>T p.R361C 18:51065548-51065548 14
3 COSM6191487 PREX2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.107G>T p.R36L 8:67952501-67952501 14
4 COSM6191489 NOTCH2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.3359G>A p.C1120Y 1:119937445-119937445 14
5 COSM2006821 KMT2D thymus,NS,thymic carcinoma,undifferentiated carcinoma c.11824C>T p.R3942W 12:49032071-49032071 14
6 COSM133763 KIT thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1657T>A p.Y553N 4:54727425-54727425 14
7 COSM6191682 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2921C>T p.A974V 23:45078488-45078488 14
8 COSM6196604 IL7R thymus,NS,thymic carcinoma,undifferentiated carcinoma c.537+1G>T p.? 5:35871214-35871214 14
9 COSM6191486 FAT1 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12706A>G p.K4236E 4:186596834-186596834 14
Sources

Expression for Thymus Cancer

About this section
Search GEO for disease gene expression data for Thymus Cancer.
Sources

Pathways for Thymus Cancer

About this section

Pathways related to Thymus Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 66
Show member pathways
 13.02 EGFR KIT MUC1 PIK3R2 POMC PSMB11
2
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.19 EGFR KIT PIK3R2 PSMB11 TP53
3
Hematopoietic cell lineage 37
11.57 CD5 DNTT KIT
4
Glucocorticoid receptor regulatory network 1
11.41 KRT5 POMC TP53
5
Bladder cancer 37 1
11.3 EGFR PIK3R2 TP53
6
UVA-Induced MAPK Signaling 64
Show member pathways
 11.23 EGFR PIK3R2 TP53
7
Central carbon metabolism in cancer 37
10.74 EGFR KIT PIK3R2 TP53
Sources

GO Terms for Thymus Cancer

About this section

Biological processes related to Thymus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cerebral cortex cell migration GO:0021795 8.96 EGFR NKX2-1
2 tongue development GO:0043586 8.62 EGFR KIT

Molecular functions related to Thymus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.16 EGFR KIT
2 protein phosphatase binding GO:0019903 9.13 EGFR PIK3R2 TP53
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.8 EGFR KIT PIK3R2
Sources

Sources for Thymus Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....